Calcification and cardiovascular problems in renal failure

Kidney International, Supplement

Volumn 67, Issue 94, 2005, Pages

  Ketteler, Markus ^a   Gross, Marie Luise ^a   Ritz, Eberhard ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Calcification; Fetuin; Hyperparathyroidism; Hyperphosphatemia; Inhibitors

Indexed keywords

FETUIN; OSTEOCALCIN; OSTEOPROTEGERIN; PYROPHOSPHATE; CALCIUM ACETATE; CALCIUM CARBONATE; OSTEOCLAST DIFFERENTIATION FACTOR; PHOSPHATE BINDING AGENT; PHOSPHORUS;

BLOOD VESSEL CALCIFICATION; BONE TURNOVER; CALCIFICATION; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; CORONARY ARTERY ATHEROSCLEROSIS; HEART DEATH; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; KIDNEY FAILURE; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SURVIVAL; CALCINOSIS; CHRONIC KIDNEY FAILURE; PATHOLOGY; REVIEW; SECONDARY HYPERPARATHYROIDISM; BODY MASS; CORONARY ARTERY BLOOD FLOW; CREATININE CLEARANCE; DIET RESTRICTION; DIET SUPPLEMENTATION; DIET THERAPY; ELECTRON BEAM TOMOGRAPHY; HEALTH HAZARD; HEART FUNCTION; HYPERPARATHYROIDISM; ISCHEMIC HEART DISEASE; MALNUTRITION; NONHUMAN; RISK FACTOR;

CALCINOSIS; CARDIOVASCULAR DISEASES; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC;

EID: 15944362166     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (66)

1. STANBURY SW, LUMB GA: Parathyroid function in chronic renal failure. A statistical survey of the plasma biochemistry in azotaemic renal osteodystrophy. Q J Med 35:1-23, 1966
2. NAVEH-MANY T, BELL O, SILVER J, KILAV R: Cis and trans acting factors in the regulation of parathyroid hormone (PTH) mRNA stability by calcium and phosphate. FEBS Lett 529:60-64, 2002
3. MOZ Y, SILVER J, NAVEH-MANY T: Characterization of cis-acting element in renal NaPi-2 cotransporter mRNA that determines mRNA stability. Am J Physiol Renal Physiol 284:F663-670, 2003
4. NAVEH-MANY T, RAHAMIMOV R, LIVNI N, SILVER J: Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. J Clin Invest 96:1786-1793, 1995
5. KROOK L: Dietary calcium-phosphorous and lameness in the horse. Cornell Vet 58(Suppl):58-73, 1968
6. POND WG, TODD GC, DUNN JA, et al: A summary of observations on control of atrophic rhinitis and virus pig pneumonia in swine. Vet Med Small Anim Clin 62:67-72, 1967
7. BLOCK GA, HULBERT-SHEARON TE, LEVIN NW, PORT FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31:607-617, 1998
8. GANESH SK, STACK AG, LEVIN NW, et al: Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12:2131-2138, 2001
9. AMANN K, GROSS ML, LONDON GM, RITZ E: Hyperphosphataemia-A silent killer of patients with renal failure? Nephrol Dial Transplant 14:2085-2087, 1999
10. AMANN K, TORNIG J, KUGEL B, et al: Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. Kidney Int 63:1296-1301, 2003
11. GUERIN AP, LONDON GM, MARCHAIS SJ, METIVIER F: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15:1014-1021, 2000
12. ROSTAND SG, DRUEKE TB: Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 56:383-392, 1999
13. LONDON GM, PANNIER B, GUERIN AP, et al: Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: Follow-up of an interventional study. J Am Soc Nephrol 12:2759-2767, 2001
14. BLOCK GA, PORT FK: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis 35:1226-1237, 2000
15. WEINREICH T, RAMBAUSEK M, RITZ E: Is control of secondary hyperparathyroidism optimal with the currently used calcium concentration in the CAPD fluid? Nephrol Dial Transplant 6:843-845, 1991
16. HSU CH: Are we mismanaging calcium and phosphate metabolism in renal failure? Am J Kidney Dis 29:641-649, 1997
17. HOU SH, ZHAO J, ELLMAN CF, et al: Calcium and phosphorus fluxes during hemodialysis with low calcium dialysate. Am J Kidney Dis 18:217-224, 1991
18. ZUCCHELLI P, SANTORO A: Inorganic phosphate removal during different dialytic procedures. Int J Artif Organs 10:173-178, 1987
19. MUCSI I, HERCZ G, ULDALL R, et al: Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int 53:1399-1404, 1998
20. ABBOTT KC, GLANTON CW, TRESPALACIOS FC, et al: Body mass index, dialysis modality, and survival: Analysis of the United States Renal Data System Dialysis Morbidity and Mortality Wave II Study. Kidney Int 65:597-605, 2004
21. PORT FK, ASHBY VB, DHINGRA RK, et al: Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients. J Am Soc Nephrol 13:1061-1066, 2002
22. GOODMAN WG, GOLDIN J, KUIZON BD, et al: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478-1483, 2000
23. CHERTOW GM, BURKE SK, RAGGI P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-252, 2002
24. TAMASHIRO M, ISEKI K, SUNAGAWA O, et al: Significant association between the progression of coronary artery calcification and dyslipidemia in patients on chronic hemodialysis. Am J Kidney Dis 38:64-69, 2001
25. JOY MS, FINN WF: Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: A new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 42:96-107, 2003
26. D'HAESE PC, SPASOVSKI GB, SIKOLE A, et al: A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int (Suppl 85):S73-S78, 2003
27. BEHETS GJ, VERBERCKMOES SC, D'HAESE PC, DE BROE ME: Lanthanum carbonate: A new phosphate binder. Curr Opin Nephrol Hypertens 13:403-409, 2004
28. BLOCK GA, MARTIN KJ, DE FRANCISCO AL, et al: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516-1525, 2004
29. STEVENS LA, DJURDJEV O, CARDEW S, et al: Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: Evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 15:770-779, 2004
30. LONDON GM, MARTY C, MARCHAIS SJ, et al: Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 15:1943-1951, 2004
31. SCHWARZ U, BUZELLO M, RITZ E, et al: Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 15:218-223, 2000
32. FUESSL RT, KRANENBERG E, KIAUSCH U, et al: Vascular remodeling in atherosclerotic coronary arteries is affected by plaque composition. Coron Artery Dis 12:91-97, 2001
33. OH J, WUNSCH R, TURZER M, et al: Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 106:100-105, 2002
34. STEFENELLI T, ABELA C, FRANK H, et al: Cardiac abnormalities in patients with primary hyperparathyroidism: Implications for follow-up. J Clin Endocrinol Metab 82:106-112, 1997
35. HEDBACK G, ODEN A: Increased risk of death from primary hyperparathyroidism-An update. Eur J Clin Invest 28:271-276, 1998
36. BRAUN J, OLDENDORF M, MOSHAGE W, et al: Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 27:394-401, 1996
37. GOODMAN WG, LONDON G, AMANN K, et al: Vascular calcification in chronic kidney disease. Am J Kidney Dis 43:572-579, 2004
38. RAGGI P, BOULAY A, CHASAN-TABER S, et al: Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 39:695-701, 2002
39. BURSZTYN M, MOTRO M, GROSSMAN E, SHEMESH J: Accelerated coronary artery calcification in mildly reduced renal function of high-risk hypertensives: A 3-year prospective observation. J Hypertens 21:1953-1959, 2003
40. KEELAN PC, BIELAK LF, ASHAI K, et al: Long-term prognostic value of coronary calcification detected by electron-beam computed tomography in patients undergoing coronary angiography. Circulation 104:412-417, 2001
41. MATSUOKA M, ISEKI K, TAMASHIRO M, et al: Impact of high coronary artery calcification score (CACS) on survival in patients on chronic hemodialysis. Clin Exp Nephrol 8:54-58, 2004
42. LONDON GM, GUERIN AP, MARCHAIS SJ, et al: Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18:1731-1740, 2003
43. WANG AY, WANG M, Woo J, et al: Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: A prospective study. J Am Soc Nephrol 14:159-168, 2003
44. AMANN K, WOLF B, NICHOLS C, et al: Aortic changes in experimental renal failure: Hyperplasia or hypertrophy of smooth muscle cells? Hypertension 29:770-775, 1997
45. JONO S, MCKEE MD, MURRY CE, et al: Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87:E10-17, 2000
46. TINTUT Y, PATEL J, TERRITO M, et al: Monocyte/macrophage regulation of vascular calcification in vitro. Circulation 105:650-665, 2002
47. MOE SM, O'NEILL KD, DUAN D, et al: Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 61:638-647, 2002
48. MOE SM, DUAN D, DOEHLE BP, O'NEILL KD, CHEN NX: Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int 63:1003-1011, 2003
49. FARZANEH-FAR A, PROUDFOOT D, SHANAHAN C, WEISSBERG PL: Vascular and valvar calcifications: Recent advances. Heart 85:13-17, 2001
50. KETTELER M, WANNER C, METZGER T, et al: Deficiencies of calcium-regulatory proteins in dialysis patients: A novel concept of cardiovascular calcification in uremia. Kidney Int (Suppl 84):S84-S87, 2003
51. VATTIKUTI R, TOWLER DA: Osteogenic regulation of vascular calcification: An early perspective. Am J Physiol Endocrinol Metab 286:E686-E696, 2004
52. LUO G, DUCY P, McKEE MD, et al: Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386:78-81, 1997
53. Case Records of the Massachussets General Hospital. New Engl J Med 345:1119-1124, 2001
54. COATES T, KIRKLAND GS, DYMOCK RB, et al: Cutaneous necrosis from calcific uremic arteriolopathy. Am J Kidney Dis 32:384-391, 1998
55. GOODMAN WG, LONDON G, AMANN K, et al: Vascular Calcification Work Group: Vascular calcification in chronic kidney disease. Am J Kidney Dis 43:572-579, 2004
56. BUCAY N, SAROSI I, DUNSTAN CR, et al: Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260-1268, 1998
57. SIMONET WS, LACEY DL, DUNSTAN CR, et al: Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89:309-319, 1997
58. NITTA K, AKIBA T, UCHIDA K, et al: The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis 42:303-309, 2003
59. SCHINKE T, AMENDT C, TRINDL A, et al: The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. J Biol Chem 271:20789-20796, 1996
60. JAHNEN-DECHENT W, SCHINKE T, TRINDL A, et al: Cloning and targeted deletion of the mouse fetuin gene. J Biol Chem 272:31496-31503, 1997
61. SCHAFER C, HEISS A, SCHWARZ A, et al: The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 112:357-366, 2003
62. KETTELER M, BONGARTZ P, WESTENFELD R, et al: Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: A cross-sectional study. Lancet 361:827-833, 2003
63. RUTSCH F, RUF N, VAINGANKAR S, et al: Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification. Nat Genet 34:379-381, 2003
64. HO AM, JOHNSON MD, KINGSLEY DM: Role of the mouse ank gene in control of tissue calcification and arthritis. Science 289:265-270, 2000
65. ALFREY AC, SOLOMONS CC: Bone pyrophosphate in uremia and its association with extraosseous calcification. J Clin Invest 57:700-705, 1976
66. LOMASHVILLI KA, COBBS S, HENNIGAR R A, et al: Phosphate-induced vascular calcification: Role of pyrophosphate and osteopontin. J Am Soc Nephrol 15:1392-1401, 2004